Other languages Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
8.12 ^USD	+0.12%		+4.77%	-29.02%

Mar. 28	Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	CI
Feb. 29	Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

La biotech helvétique a profité d'un regain de fonds en 2023	Apr. 23
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29
Top Premarket Decliners	Feb. 29
Ironwood says bowel disease treatment meets main goal in late-stage trial	Feb. 29
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing	Feb. 15
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing	Feb. 15
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing	Feb. 15
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	Feb. 15
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 15
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 15
Ironwood Pharmaceuticals 2024 Revenue Outlook Trails Consensus; 2023 Guidance Maintained	Jan. 08
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024	Jan. 08
Pharma und Gesundheit: weitere Konsolidierung	Dec. 13
Farma en gezondheid: consolidatie gaat door	Dec. 12
Farmaceutica e salute: continua il consolidamento	Dec. 11
Farmacia y salud: La consolidación continúa	Dec. 11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Other languages

Filters